ROCHE DIAGNOSTICS AND ORASURE TECHNOLOGIES SIGN LETTER OF INTENT TO DEVELOP FULLY AUTOMATED ORAL FLUID DRUGS OF ABUS ASSAYS

Roche Diagnostics signed a letter of intent to negotiate an agreement for the joint development and commercialization of homogeneous fully-automated oral fluid drugs of abuse assays that can run on random access chemistry analyzers with OraSure Technologies, Inc. The oral fluid assays will be developed for use with OraSure's Intercept oral specimen collection device and Roche's KIMS (kinetic interaction of microparticles in solution) technology. The oral fluid assays will be designed to run on various automated analyzers and to allow oral fluid samples to be processed with the same efficiency as current urine based tests. Among the key potential benefits to laboratories will be increased efficiencies and quicker turnaround times.

Boursorama (http://www.boursorama.com/infos/actualites/detail_actu_societes.phtml?news=3704465)